Nintedanib Capsule
Product Images NDC 43598-148

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nintedanib (NDC 43598-148). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Nintedanib Capsules 100 mg by Dr. Reddy's Laboratories Inc., containing 60 capsules. The label includes dosage information, storage instructions, NDC 43598-148-60, a barcode, QR code for patient information, and regulatory details. The design features blue and orange text with the Dr. Reddy's logo.*

FDA Label Image

Container2 (Container2)

Nintedanib Capsules 150 mg oral capsules label showing the active ingredient strength, quantity of 60 capsules, and the labeler Dr. Reddy's Laboratories Inc. The label includes storage instructions and a QR code linking to the patient information sheet.*

FDA Label Image

Figure1 (Figure1)

Line graph showing mean observed forced vital capacity (FVC) change from baseline over time in weeks, comparing two groups: placebo and Nintedanib 150 mg twice daily. The y-axis measures the mean FVC change in milliliters, and the x-axis shows time points from 2 to 52 weeks. Data points include error bars representing standard error of the mean (SEM). The graph demonstrates a greater decline in FVC for placebo compared to Nintedanib over the study period.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier style survival curve chart comparing percentage of patients over time by absolute change in predicted forced vital capacity (FVC) from baseline to Week 62. Two curves represent placebo (dotted line) and Nintedanib 150 mg (solid line) groups, showing higher percentages of patients with improvements in FVC in the Nintedanib group.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier survival estimate graph depicting time to death over 52 weeks (days) comparing Nintedanib 150 mg twice daily versus placebo. The chart includes survival percentages on the y-axis and time in days on the x-axis, with a hazard ratio of 0.70 (95% CI: 0.43 to 1.12) noted. The number of subjects at risk is shown below the x-axis over time.*

FDA Label Image

Figure4 (Figure4)

A forest plot chart comparing placebo and Nintedanib 150 mg twice daily (150bid) groups, showing differences in adjusted rate of decline in forced vital capacity (FVC) over 52 weeks among different interstitial lung disease (ILD) populations and subgroups, with 95% confidence intervals. The chart displays point estimates and confidence intervals indicating favorability toward placebo or Nintedanib 150 mg 150bid.*

FDA Label Image

Figure5 (Figure5)

A line graph comparing mean change from baseline in observed FVC (mL) over 52 weeks between placebo and Nintedanib 150 mg twice daily groups. The graph plots time points from 2 to 52 weeks on the x-axis and change in FVC on the y-axis, showing less decline in FVC with Nintedanib compared to placebo. Patient numbers at each time point are annotated below the graph for both groups.*

FDA Label Image

Figure6 (Figure6)

A horizontal bar chart comparing the percent change from baseline in FVC (mL) at Week 52 between placebo and Nintedanib 150 mg bid groups. The chart shows proportions of patients with improvement and worsening or missing data, highlighting percentages for different ranges of FVC change. The left side represents the placebo group, and the right side represents the Nintedanib group with hatched bars.*

FDA Label Image

Structure (Structure)

Chemical structure of nintedanib, showing its molecular framework including aromatic rings, nitrogen atoms, and functional groups consistent with the active ingredient nintedanib in capsule form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.